GSK (LON:GSK) PT Lowered to GBX 1,850

GSK (LON:GSK) had its target price lowered by Deutsche Bank Aktiengesellschaft from GBX 1,950 ($25.08) to GBX 1,850 ($23.80) in a research report issued on Wednesday, Digital Look reports. The brokerage presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 22.80% from the company’s current price.

GSK has been the subject of several other research reports. Citigroup cut their price objective on shares of GSK from GBX 2,120 ($27.27) to GBX 1,900 ($24.44) and set a “buy” rating for the company in a research report on Friday, July 5th. Barclays reaffirmed an “equal weight” rating and set a GBX 1,725 ($22.19) price objective on shares of GSK in a research report on Tuesday, May 7th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research report on Monday. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 ($27.01) price objective on shares of GSK in a research report on Thursday, June 27th. Finally, Shore Capital reaffirmed a “buy” rating on shares of GSK in a research report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and a consensus price target of GBX 1,805.71 ($23.23).

GSK Price Performance

LON GSK opened at GBX 1,506.50 ($19.38) on Wednesday. The company has a quick ratio of 0.73, a current ratio of 0.87 and a debt-to-equity ratio of 134.34. GSK has a 12-month low of GBX 1,330.19 ($17.11) and a 12-month high of GBX 1,823.50 ($23.46). The company has a market capitalization of £61.47 billion, a PE ratio of 1,382.11, a price-to-earnings-growth ratio of 1.19 and a beta of 0.27. The firm’s 50 day moving average is GBX 1,586.30 and its 200-day moving average is GBX 1,636.22.

Insider Buying and Selling

In related news, insider Wendy Becker bought 446 shares of the business’s stock in a transaction on Thursday, June 20th. The stock was acquired at an average price of GBX 1,614 ($20.76) per share, for a total transaction of £7,198.44 ($9,259.63). 1.60% of the stock is currently owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.